Apeiron Acquisition Vehicle I

General Information
Business:	(Incorporated in the Cayman Islands) We are a newly organized blank check company. We have not selected a specific sector or industry as a focus in our search for acquisition targets. Through our management team, we expect to have differentiated access to deal flow extending beyond the U.S., with a particular focus on Europe. Lorin Van Nuland, our CEO and CFO since August 2025, has over 15 years of experience in venture capital, public and private equity markets, M&A and corporate leadership. From July 2023 to April 2024, Mr. Van Nuland served as head of proprietary investments at Apeiron, where he oversaw its balance sheet of assets and spearheaded the incubation and development of portfolio companies across cryptocurrency, deep tech, life sciences, real estate, experiences, hospitality and sports. Dr. Juliette Han, who will serve as one of our directors on the commencement of trading of our securities on Nasdaq, has served as CFO and COO of Cambrian Biopharma since February 2020. (Note: Apeiron Acquisition Vehicle I filed its S-1 for its SPAC IPO on Feb. 4, 2026, and disclosed the terms: 7 million units at $10.00 each to raise $70 million. Each unit consists of one share of stock and one-half of one redeemable warrant.)
Industry:	BLANK CHECKS
Employees:	0
Founded:	2025
Contact Information
Address	1330 Ave of the Americas, 23rd Floor New York, NY 10019 (212) 653-6882
Phone Number	(212) 653-6882
Web Address
View Prospectus:	Apeiron Acquisition Vehicle I
Financial Information
Market Cap	$95.8mil
Revenues	$0 mil (last 12 months)
Net Income	$0 mil (last 12 months)
IPO Profile
Symbol	APNU
Exchange	NASDAQ
Shares (millions):	7.0
Price range	$10.00 - $10.00
Est. $ Volume	$70.0 mil
Manager / Joint Managers	Berenberg
CO-Managers
Expected To Trade:
Status:	TBA
Quiet Period Expiration Date:	Available only to Subscribers
Lock-Up Period Expiration Date:	Available only to Subscribers
SCOOP Rating	Available only to Subscribers
Rating Change	Available only to Subscribers

Apeiron Acquisition Vehicle I

(Incorporated in the Cayman Islands)

We are a newly organized blank check company. We have not selected a specific sector or industry as a focus in our search for acquisition targets. Through our management team, we expect to have differentiated access to deal flow extending beyond the U.S., with a particular focus on Europe.

Dr. Juliette Han, who will serve as one of our directors on the commencement of trading of our securities on Nasdaq, has served as CFO and COO of Cambrian Biopharma since February 2020.

(Note: Apeiron Acquisition Vehicle I filed its S-1 for its SPAC IPO on Feb. 4, 2026, and disclosed the terms: 7 million units at $10.00 each to raise $70 million. Each unit consists of one share of stock and one-half of one redeemable warrant.)